NIH cannabis research

The U.S. National Institutes of Health (NIH) funds cannabis and cannabinoid research across multiple institutes, principally NIDA (addiction and harms), the National Cancer Institute (NCI, symptom management and oncology), the National Center for Complementary and Integrative Health (NCCIH, minor cannabinoids and pain), the National Institute of Neurological Disorders and Stroke (NINDS, epilepsy and neurodegeneration), and the National Institute of Mental Health (NIMH, psychosis and cannabis use disorder). Funding is tracked publicly through NIH RePORTER. ⚠️ As of April 2026, the portfolio's institutional home is in flux: the FY2026 President's Budget proposed a ~40% NIH cut (to ~$27 billion) and a consolidation eliminating NCCIH outright and merging NIDA, NIAAA, and NIMH. Congress has not enacted these changes, but NIH has terminated or rescinded numerous grants and is operating under constrained indirect-cost rules pending litigation. Researchers should verify current RFAs directly with NIH. → See also: NIDA.